Comparing between HLA‐matched sibling donor allogenic HSCT and non‐sibling matched related donor allogenic HSCT outcome in pediatric patients; single center retrospective study

Abstract

AbstractBackgroundExtended family donor search other than siblings may yield an HLA matched donor in communities with high rate of consanguinity. The outcome of patients who are transplanted from non‐sibling matched related donors (NS‐MRD) including engraftment and graft versus host disease (GVHD) are scarce in comparison with matched sibling donor (MSD).MethodsWe retrospectively reviewed the outcome of all our pediatric hematopoietic stem cell transplantation (HSCT) patients who had non‐sibling matched related donor and controlled them with matched sibling donor HSCT (based on age, indication of HSCT, conditioning regimen, GVHD prophylaxis, serotherapy, stem cell source and cytomegalovirus status).ResultsA total of 76 patients were reviewed during study period. Thirty patients (39.5%) in NS‐MRD arm and 46 patients in MSD (60.5%) were identified after matching in age, disease, and conditioning regimens. All patients had similar approach including stem cell source and GVHD prophylaxis (CNI + 2nd agent). Out of the NS‐MRD group, 18 patients (59%) had one of their parents as a donor and the rest as second degree relatives. Both groups were equally distributed and were homogeneous. Both groups had no statistically significant difference in outcome including engraftment, GVHD and Chimerism tests results. GVHD was seen in (13%) NS‐MRD patients compared to (11%) in MSD patients. All patients remain alive with median follow up of 1249 days (431–3525).ConclusionsThis study showed no significant difference in allogenic HSCT outcomes between matched sibling donors and non‐sibling matched related donors and support using the same management approach in terms of conditioning therapy, GVHD prophylaxis, and serotherapy only if indicated.